CTOs on the Move

The Schwartz Group

www.theschwartzgroup.com

 
The Schwartz Group is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Avon Podiatry

Avon Podiatry is a Avon, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northern Light Health

Northern Light Health exists to make healthcare work for you. That is our mission. That is our purpose. Northern Light Health is the most expansive integrated health care system in Maine. We provide care to people from Portland to Presque Isle and from Blue Hill to Greenville. We are comprised of nine member hospitals with 584 long-term beds, a single physician-led medical group, eight nursing homes, five emergency transport members, 37 primary care locations, and we employ more than 12,000 people in Maine.

Briarwood Manor

Briarwood Manor is a Lockport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QuadraMed

Quadramed is an Electronic Document Management solution for your healthcare network that acts as a repository for downloaded and scanned documents.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.